Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML） is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in MDS, AML. SEO and diligence focus: Decitabine, Cytarabine, aclacinomycin, Granulocyte colony-stimulating factor, HLA haploidentical mononuclear cells infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.